Venetoclax Combined With Azacitidine Plus Homoharringtonine Versus Venetoclax Combined With Azacitidine for Relapsed/Refractory Acute Myeloid Leukemia：an Open-label, Multicentre, Randomised Phase 3 Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT05457361

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:38:34.837253+00:00

Published At

2022-07-14T00:00:00+00:00

Record Updated At

2022-07-14

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Venetoclax Combined With Azacitidine Plus Homoharringtonine", "Venetoclax Combined With Azacitidine"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2022-07-14"

protocolSection.identificationModule.nctId

"NCT05457361"

protocolSection.identificationModule.officialTitle

"Venetoclax Combined With Azacitidine Plus Homoharringtonine Versus Venetoclax Combined With Azacitidine for Relapsed/Refractory Acute Myeloid Leukemia\uff1aan Open-label, Multicentre, Randomised Phase 3 Trial"

protocolSection.statusModule.overallStatus

"UNKNOWN"

protocolSection.designModule.phases

["PHASE3"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

""

Study condition terms

• Venetoclax Combined With Azacitidine Plus Homoharringtonine (protocolSection.conditionsModule.conditions)
• Venetoclax Combined With Azacitidine (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.